Vaccination provided ample protection for kids with and without underlying conditions ...
During eight respiratory illness seasons, estimated influenza vaccine effectiveness (VE) against death in US children was 80% ...
VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...
A new kind of flu vaccine is moving a step closer to the U.S. market.
Coadministration was not associated with an increased risk of side effects ...
Since 1945, the U.S. military mandated flu vaccines—until Hegseth changed things earlier this year.
The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely ...
All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.